TOHO HOLDINGS CO., LTD. Announces Capital Alliance with HekaBio K.K.

March 19, 2018


Corporate Representative: Norio Hamada,

             Chairman of the Board and Representative Director

(First Section of Tokyo Stock Exchange Securities Code:8129)

Contact: Makoto Kawamura, Corporate Officer, General Manager,

Public and Investor Relations Department (TEL: 81-3-6838-2803)

Announcement about Capital Alliance with HekaBio K.K.

TOHO HOLDINGS CO., LTD. (Headquarters: Tokyo; Chairman of the Board and Representative Director: Norio Hamada; hereinafter, “TOHO HOLDINGS”) announces today it has decided to subscribe to the third-party share issuance by HekaBio K.K. (Headquarters: Tokyo; CEO: Robert Evans Claar; hereinafter, “HekaBio"), a bio venture company. Specifics are as outlined below:

1. Reason for capital alliance

TOHO HOLDINGS is a corporate group active in medical, nursing and healthcare fields, engaged in pharmaceutical wholesaling, dispensing pharmacy, manufacturing and sales of pharmaceuticals, and development and provision of customer support systems under the corporate slogan "Total Commitment to Good Health". TOHO HOLDINGS also proactively promotes initiatives for regional medical collaboration, nursing and home care.

HekaBio endeavors to contribute to the advancement of medical care by introducing innovative, novel therapeutics from overseas for patients fighting intractable cancer and autoimmune/inflammatory disease. HekaBio’s leadership conducts businesses based on experience from previously established Japan-based companies including Junicon K.K. (est. 1992), a healthcare market research consulting firm for Japanese, American and European companies, and Vorpal Technologies K.K. (est. 2013), a medical device and pharmaceutical CRO.

TOHO HOLDINGS and HekaBio share the same philosophy of contribution to society and medical care. Through this investment, TOHO HOLDINGS will collaborate in the development, marketing and distribution of new and innovative therapeutics in Japan.

2. Overview of HekaBio K.K.

(1) Company name: HekaBio K.K.

(2) Location: Yashima Bldg 3F, 2-7-14 Toranomon, Minato-ku, Tokyo

(3) Representative: Robert Evans Claar, CEO

(4) Established: November 2016 (Company name changed to HekaBio K.K. in November 2017)

(5) Business content: Import, development, manufacturing and sales of pharmaceutical,

medical device, diagnostic and regenerative medicine products

(6) Capital: JPY 94.514 million

(7) Fiscal year end: December 31

(8) Number of employees: 7

(9) Contact: Ben Pratt, COO (TEL: 81-3-6205-7585, email:

3. Number of shares, method, price, shares owned before and after acquisition and share acquisition date

(1) Number of shares to be acquired: 1,400 Class A shares

(2) Acquisition method: Subscription to third-party allotment of shares issued by HekaBio

(3) Acquisition price: Undisclosed

(4) Shares owned prior to acquisition: 0 (Ownership percentage: 0%)

(5) Shares owned after acquisition: 1,400 (Fully diluted ownership percentage: 6%)

(6) Date of share acquisition: March 20, 2018

4. Forward looking outlook

Impact to consolidated performance is minor.




ヘカバイオ株式会社(東京都中央区日本橋本石町3-3-16)は2021年1月29日付にて4億円の第三者割当増資を行いました。 今回の増資により調達した資金は、今後当社が開発を手掛けるポートフォリオを拡充させるために活用いたします。 当社は、人々の医療と健康への貢献を使命として、世界への窓口として日本にベースに置き、海外の製品の導入に特化して開発や市場化を行っています。がん、線維性疾患、自己免疫性炎症


~バイオサイエンスの新たなイノベーションについて認知度とアクセシビリティの向上を図る~ 2020年9月23日 ヘカバイオ株式会社(本社:東京都中央区、代表取締役兼CEO:クレア・ロバート、以下:ヘカバイオ)と株式会社コスモ・ピーアール(本社:東京都港区、代表取締役社長:佐藤玖美、以下:コスモ)は、コスモがヘカバイオに出資し、両社が戦略的パートナーシップを締結したことを発表します。本パートナーシップ

オフィス移転のお知らせ Office Relocation

2020年8月24日より下記へ移転いたします。 〒103-0021 東京都中央区日本橋本石町3丁目3番16号 日本橋室町ビル8階 電話番号・FAX番号 変更無し 最寄り駅: 地下鉄各線 三越前駅 A8出口 徒歩3分 Effective August 24, 2020, HekaBio will relocate to new premises as follows. Nihonbashi Muro





© 2020 HekaBio K. K.​